S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

$19.43
+0.50 (+2.64%)
(As of 06/5/2023 ET)
Compare
Today's Range
$18.74
$19.58
50-Day Range
$16.69
$28.58
52-Week Range
$8.80
$34.13
Volume
460,464 shs
Average Volume
506,562 shs
Market Capitalization
$566.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.29

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
158.8% Upside
$50.29 Price Target
Short Interest
Healthy
16.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.43mentions of BioXcel Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.87) to ($5.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

177th out of 986 stocks

Pharmaceutical Preparations Industry

73rd out of 478 stocks


BTAI stock logo

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. It also focuses on utilizing cutting-edge technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Where BioXcel Therapeutics Stands With Analysts
See More Headlines

BTAI Price History

BTAI Company Calendar

Last Earnings
5/08/2023
Today
6/05/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
89
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$50.29
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+162.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-165,760,000.00
Pretax Margin
-32,199.83%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$2.74 per share

Miscellaneous

Free Float
18,721,000
Market Cap
$559.29 million
Optionable
Not Optionable
Beta
1.09

Social Links


Key Executives

  • Vimal D. MehtaVimal D. Mehta
    President, Chief Executive Officer & Director
  • Richard I. Steinhart
    Chief Financial & Accounting Officer, Senior VP
  • Frank D. Yocca
    Chief Scientific Officer & Senior Vice President
  • Vincent J. O'Neill
    Chief Medical Officer & Senior Vice President
  • Javier Rodriguez
    Secretary, Chief Legal Officer & Senior VP













BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12-month price objectives for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $22.00 to $76.00. On average, they anticipate the company's stock price to reach $50.29 in the next year. This suggests a possible upside of 162.2% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2023?

BioXcel Therapeutics' stock was trading at $21.48 on January 1st, 2023. Since then, BTAI shares have decreased by 10.7% and is now trading at $19.18.
View the best growth stocks for 2023 here
.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,350,000 shares, a drop of 5.4% from the April 30th total of 3,540,000 shares. Based on an average trading volume of 518,100 shares, the short-interest ratio is currently 6.5 days. Approximately 16.7% of the company's stock are short sold.
View BioXcel Therapeutics' Short Interest
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Monday, May, 8th. The company reported ($1.84) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by $0.28. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.50 million. During the same period in the prior year, the business posted ($1.12) earnings per share.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.74%), State Street Corp (6.04%), BlackRock Inc. (4.72%), Wellington Management Group LLP (4.60%), Artemis Investment Management LLP (3.38%) and Geode Capital Management LLC (1.31%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $19.18.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $559.29 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($6.63) on an earnings per share basis.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -